tbuckley/cabot-search huggingface dataset:
Role of illness in male professional football: not a major contributor to time loss
Authors: John Bjørneboe, Karolina Kristenson, Markus Waldén, Håkan Bengtsson, Jan Ekstrand, Martin Hägglund, Ola Rønsen, Thor Einar Andersen
Journal: British Journal of Sports Medicine (2016)

There are limited data on the nature, type and incidence of illness in football. Previous studies indicate that gastrointestinal and respiratory tract illnesses are most common.To describe the incidence and burden of illness in male professional football.Over the 4-year study period, 2011-2014, 73 professional football teams in Europe participated, with a total of 1 261 367 player-days recorded. All time-loss illnesses were recorded by the medical staff of each club. A recordable illness episode was any physical or psychological symptom (not related to injury) that resulted in the player being unable to participate fully in training or match play.A total of 1914 illness episodes were recorded. The illness incidence was 1.5 per 1000 player-days, meaning that, on average, a player experienced an illness episode every second season, with a median of 3 days absence per illness episode. Severe illness (absence >4 weeks) constituted 2% of all illnesses. Respiratory tract illness was the most common (58%), followed by gastrointestinal illness (38%). Respiratory tract illness, gastrointestinal illness and cardiovascular illness caused the highest illness burden.The illness incidence among male professional football players is low compared with the injury incidence. We found that the highest illness burden was caused by illness to the respiratory tract, gastrointestinal tract and cardiovascular system.
Reply to Mannath &amp; Ragunath
Authors: F. van Vilsteren, E. Schoon, J. Bergman
Journal: Endoscopy (2012)

We thank Drs. Mannath and Ragunath for their thoughful comments on our study. They propose a one-to-one training program in endoscopic resection according to the traditional fellow-in-training approach, resulting in a gradual process towards independent practice. Although we agree that such an interaction enables gradual and prolonged training we thought that this would be less applicable in our country for teaching endoscopic management of early neoplasia in the upper gastrointestinal tract. We considered this to be a postgraduate training for which a certain level of endoscopic experience would be required. In addition, we wanted to train a limited number of centers, preferably geographically spread across the Netherlands. Finally, we wanted to ensure that centralized treatment would be available within a relatively short period of time (2 years). The traditional approach suggested by Mannath & Ragunath would not have enabled us to facilitate centralization to selected centers at this scale and time frame. In addition, the fellow-in-training approach does not ensure centralization of diagnosis and treatment, since the fellow trained may not necessarily be appointed in centers that are suitable for a referral function in this field and building such a referral function requires more than just the presence of a trained endoscopist.
Inhibition of Calcitonin Gene-Related Peptide and Insulin-Like Growth Factor: A Potential New Therapeutic Strategy To Reduce Bone Pain in Bone Metastases of Breast Cancer.
Authors: T. Sakurai, T. Sakurai, T. Sakurai, T. Umemura, E. Jinta, T. Suzuma, P. Williams, G. Yoshimura, H. Wakabayashi, T. Sakurai, T. Yoneda, T. Yoneda
Journal: Cancer Research (2009)

Abstract Bone pain caused by bone metastases is one of the most common complications in patients with breast cancer. However, the precise molecular mechanism of bone pain is unknown. We have shown that the acid released upon bone resorption by osteoclasts and the transient receptor potential vanilloid receptor (TRPV1), an acid-sensing receptor on the algetic nerves terminating at the bone, are involved in the mechanism underlying this bone pain. In this study, we investigated the relationships among TRPV1, bone-derived insulin-like growth factor-1 (IGF-1) which is released from bone due to increased bone resorption during the progression of bone metastases, and neuropeptide calcitonin gene-related peptide (CGRP) and examined whether cancer-induced bone pain can be decreased by the inhibition of IGF-1 and CGRP. To study this in vitro, we established organ cultures of mouse dorsal root ganglions (DRGs), which are the primary sensory neurons innervating bone. Culture supernatants harvested from the mouse neonatal calvariae, which had abundant growth factor in bone, showed elevated TRPV1 and CGRP mRNA expressions in mouse DRGs. These up-regulated mRNA expressions were inhibited by the administration of a TRPV1 inhibitor (I-RTX); AG1024, a specific inhibitor of IGF receptor tyrosine kinase; or zoledronate. Taken together, these results suggest that CGRP and bone-derived IGF-1 may play a role in the induction of bone pain. To approach the role of CGRP and bone-derived IGF-1 in vivo, we established a mouse model of cancer-induced bone pain by inoculating the 4T1 mouse breast cancer cells into the marrow cavity of tibiae. Tumor-inoculated tibiae showed significantly increased pain behaviors compared with the non-tumor-bearing tibiae, indicating 4T1 cells induced bone pain. RT-PCR showed elevated mRNA expression of TRPV1 and CGRP in the ipsi-lateral tumor-bearing DRGs. The administration of a CGRP inhibitor (CGRP 8-37) in a continuous manner using an ALZET osmotic pump implanted under the mouse skin; the intraperitoneal administration of AG1024; and the administration of alendronate significantly reduced pain behaviors in tumor-bearing tibiae. In addition, mRNA expression of CGRP was decreased by CGRP 8-37, and mRNA expression of TRVP1 and CGRP was also decreased by AG1024 in the ipsi-lateral DRGs. Neither of these drugs showed a direct effect on the growth of the tumor in this study. In conclusion, our results suggest that TRPV1, CGRP, and the bone-derived IGF-1 are strongly related and might play a role in breast cancer-induced bone pain. The inhibition of the CGRP and bone-derived IGF-1 could be a potential therapeutic strategy to reduce bone pain; although further investigations are required in this direction. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 1110.
Case 32-2009
Authors: Andrew M. Tager, Amita Sharma, Eugene J. Mark
Journal: New England Journal of Medicine (2009)

A 27-year-old man was seen at this hospital because of progressive dyspnea and decreased exercise tolerance during the past 2 years. Imaging studies showed diffuse pulmonary fibrosis. The patient had lighter skin than many in his family, although he reported that several family members had light skin and respiratory problems. He had a history of easy bruising. On examination, his skin was pale, and there was clubbing of the fingers and toes, normal breath sounds, pigmented irises, and horizontal nystagmus. A diagnostic procedure was performed.
Toxicity of FireMaster FF-1 and 2,2 prime ,4,4 prime ,5,5 prime -Hexabromobiphenyl in Cultures of C3H/10T 1/2 Mammalian Fibroblasts
Authors: F. Bairstow, M.-T. Hsia, D. H. Norback, J. R. Allen
Journal: Environmental Health Perspectives (1978)
Abstract 2087: miR-483-3p is an oncogene involved in nephroblastoma and in adult tumors with activated β-catenin
Authors: Angelo Veronese, Jessica Consiglio, Rosa Visone, Nicola Zanesi, Manuela Ferracin, Giovanni Lanza, Patrizia Querzoli, Adriano Angioni, Carlo Croce, Massimo Negrini
Journal: Cancer Research (2010)

Abstract The hsa-mir-483 locus is located within intron 2 of the IGF2 locus. Here, we show that the mature microRNA (miRNA) miR-483-3p is over-expressed and co-regulated with IGF2 in 100% of Wilms’ tumors. Additionally, several types of common adult cancers exhibit high or even extremely high levels of miR-483-3p. We show that the mutation status of the oncoprotein β-catenin is correlated with the expression of the miR-483-3p in hepatocarcinoma and colorectal cancer. These findings suggested an autonomous oncogenic function for this miRNA. Indeed, anti-microRNA oligonucleotide (AMO) against miR-483-3p could inhibit tumorigenicity of HepG2 cells. At the same time, no anti-tumor effect was elicited by inhibition of IGF2. The oncogenic properties of miR-483-3p were further supported by the finding that its ectopic expression could protect cells from apoptosis through the regulation of one important pro-apoptotic protein, Puma. Our results indicate that miR-483-3p can function as an anti-apoptotic oncogene in various human cancers and reveal a new potentially important target for anti-cancer therapy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2087.
AB0411 Tuberculosis Infection in Patients with Tumor Necrosis Factor Antagonists in South Korea; Retrospective Analysis Using by National Health Insurance Review and Assessment Service
Authors: S. Moon, K.-S. Shin, E.-J. Park, J. Kim, G.H. Seo
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Tumor necrosis factor-α (TNF-α) antagonists bring new hope for treating rheumatoid arthritis (RA) over the past decade. However, the subsequent increased risk of developing tuberculosis (TB) is one of the major drawbacks in patients with TNF-α antagonists. <h3>Objectives</h3> The aim of this study was to evaluate the overall incidence rate of TB in RA patients treated with TNF-α antagonists and compare of incidence rate according to type and duration of TNF-α antagonists, and history of treatment for latent TB infection (LTBI) in South Korea, TB-endemic area. <h3>Methods</h3> All RA patients treated with TNF-α antagonists registered with the Korea National Health Insurance Review and Assessment Service (HIRA) between January 2006 and December 2011 were included and retrospectively analyzed. The incidence of LTBI by screening test and of TB after starting TNF-α antagonists were reviewed. <h3>Results</h3> Total 3,573 RA patients with TNF-α antagonists were observed. Of these, 735 (21.1%) patients were treated with LTBI before starting TNF-α antagonists. One hundred-thirty two (2.6%) patients developed TB during follow-up period, and the incidence rate of TB was 583.7 per 100,000 person years (PY). The incidence rate of TB in patient with infliximab revealed 1408.1 per 100,000 PY which is the highest rate, followed by adalimumab of 1211.4 per 100,000 PY and etanercept of 618.4 per 100,000 PY. Forty-five (1648.8 per 100,000 PY), 24 (1038.2 per 100,000 PY), and 63 (647.5 per 100,000 PY) cases of TB were observed during first 6 months, 7-12 months, and 13 months or more after starting TNF-α antagonists, respectively. Among the patients who developed TB, 13 (9.8%) patients had completed treatment of LTBI. The incidence rate of TB demonstrated 477.6 per 100,000 PY and 987.7 per 100,000 PY in patients with and without history of treatment of LTBI, respectively. <h3>Conclusions</h3> The risk of TB infection increased in RA patients treated with infliximab, and during first 6 months with TNF-α antagonists. Relatively lower risk of TB infection were observed in patients treated with etanercept, and during 13 months and more after starting TNF-α antagonists compare to the rest of the RA patients. RA patients with TNF-α antagonists need watchful observation for TB infection, even in patients who had completed treatment of LTBI. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4813
O10.07 * RANDOMIZED PHASE II STUDY OF AXITINIB VS. STANDARD OF CARE IN PATIENTS WITH RECURRENT GLIOBLASTOMA
Authors: J. Duerinck, S. Du Four, F. Bouttens, V. Verschaeve, H. Everaert, S. De Raedt, A. Van Binst, B. Neyns
Journal: Neuro-Oncology (2014)

INTRODUCTION: Glioblastoma (GB) associated neo-angiogenesis is mediated by vascular endothelial growth factor receptor (VEGFR) signal transduction. Axitinib is an oral small molecule tyrosine kinase inhibitor with high affinity and specificity for the VEGF-receptors, approved for the treatment of metastatic renal cell carcinoma. METHODS: Axitinib (5 mg BID starting dose) vs. best alternative choice of therapy was studied in an open label, randomized, phase II clinical trial in patients (pts) with recurrent GB. Six-month progression-free survival (6mPFS) was the primary endpoint using Fleming's single-stage procedure. RESULTS: Between Sep 2011 and Oct 2013, 44 pts who failed surgery, RT and temozolomide were randomized 1:1 at 3 sites. Median age 54y (range 20-79), 33M/11F, WHO-PS 0/1/2/3: 6, 26, 11, and 1 pt. In the control arm 20 pts received bevacizumab and 2 pts received lomustine at standard doses. Axitinib (n = 22) was generally well tolerated. Most common axitinib related AEs consisted of dysphonia (3x G2), fatigue (6x G2, 2x G3), hypertension (5x G2), oral hyperesthesia (7x G2, 1x G3), diarrhea (2x G2, 2x G3), and hypothyroidism (3x G2). In 4 pts axitinib dosing was interrupted and subsequently dose reduced because of toxicity; in 4 other pts axitinib was dose escalated to 7 or 10 mg BID (2 pts each). The confirmed best overall tumor response rate by RANO criteria was 28% in the axitinib arm (2 CR / 4 PR) vs. 23% in the control arm (1 CR / 4 PR). Five additional pts in the axitinib-arm and 1 additional patient in the control-arm had an unconfirmed respons, and respectively 5 and 7 patients had a SD; 1pt in each arm was not evaluable for tumor response. Corticosteroids could be stopped in 4/12 and tapered in an additional 5/12 pts in the axitinib arm. At baseline all pts had an increased uptake on 18F-FET PET and a magnetic resonance spectroscopy (MRS) signal pattern showing an increased level of choline (Cho) and a decreased level of N-acetylaspartate (NAA) at the site of rGB. A decrease (-26 to -100%) of SUVmax/background on 18F-FET PET was documented in 6/7 pts on axitinib at the time of response on MRI. MRS-spectra obtained at the time of response and progression are currently being analysed. After a median follow-up of 10.5 mths, the 6mPFS for axitinib was 22% (95% CI 5-40) vs. 19% (95% CI 2-36) for the control arm. Median PFS and OS were respectively 2.9 vs. 2.6 mths, and 10.3 vs. 7.4 mths for pts treated in the axitinib vs. control arm. CONCLUSIONS: Axitinib has single-agent activity and manageable toxicity in pts with recurrent GB. The survival on the axitinib arm was comparable to that on the contemporary control arm. Tumor response on MRI is accompanied by decreased uptake of tracer on 18F-FET PET scan. Response characteristics in MRS are currently under evaluation. Further evaluation of axitinib for recurrent GB is warranted.
Intraductal ultrasonography-directed endoscopic retrograde biliary drainage without fluoroscopy
Authors: Ji-Myoung Lee, Chang-Hwan Park, Soo-Jung Rew, Ha-Na Kim, Ho-Jun Lee, In-Hyung Park, Seon-Young Park
Journal: Endoscopy (2014)

Common bile duct (CBD) stones may cause septic shock and lead to life-threatening conditions [1]. Endoscopic sphincterotomy (EST) and stone removal is an accepted method for the treatment of CBD stones [2]. EST has the potential to cause bleeding in patients with a bleeding risk. However, endoscopic retrograde biliary drainage (ERBD) can be performed effectively and safely without EST in these patients. ERBD has been performed under fluoroscopy, resulting in a relatively long duration of radiation exposure [3] [4]. Intraductal ultrasound (IDUS) provides real-time cross-sectional imaging within the bile duct. IDUS can be performed without fluoroscopy. Therefore, IDUS-directed ERBD can be used to reduce the time of radiation exposure for both examiners and patients. This report describes IDUS-directed ERBD with a plastic stent without fluoroscopy in patients with a risk of bleeding.
LATE CLINICAL OUTCOMES AFTER BIORESORBABLE OR PERMANENT POLYMER EVEROLIMUS-ELUTING STENTS: 2-YEAR RESULTS FROM THE EVOLVE II RANDOMIZED TRIAL
Authors: Dean J. Kereiakes, Ian Meredith, Stephan Windecker, Ameer Kabour, Alain Bouchard, Annapoorna Kini, Luc Janssens, Michael Foster, Robert Stoler, Thomas Stuckey, Wayne Batchelor, Thomas Christen, Dominic Allocco, Keith Dawkins
Journal: Journal of the American College of Cardiology (2016)
158 USEFULNESS OF RAPID TESTS FOR HEPATITIS B AND C VIRUS MARKERS DETECTION AMONG CRACK USERS LOCATED AT TWO BRAZILIAN GEOGRAPHICAL AREAS
Authors: L.M. Villar, E.F. da Silva, J.C. Miguel, H.M. Cruz, J.C. de Oliveira, L.P. Scalioni, R.M. Pereira, M.S. Cruz, T.M. Andrade, F.I. Bastos, N.B. dos Reis, E. Lampe
Journal: Journal of Hepatology (2012)
How Will the '4:1 Ratio' Change with Increasingly Effective Systemic Therapy.
Authors: J. Harris
Journal: Cancer Research (2009)

Abstract The 4:1 ratio between a reduction in local recurrence at 5 years and a reduction in mortality at 15 years has been well established in clinical practice. The Ratio is particularly useful to estimate the survival benefit of adding RT, particularly in the postmastectomy setting where the use of RT is not routine. It is worth noting, however, that the 4:1 ratio is an average effect that is largely based on trials without systemic therapy and does not account for the interrelated issues of (1) competing risks of local recurrence and distant metastases, (2) biologic heterogeneity, and (3) the impact of (improving) systemic therapy. If the ratio becomes less than 4:1, it means that local treatment is even more important for long-term survival. In this talk, emerging data will be presented illustrating how the '4:1 ratio' is influenced by competing risks of local recurrence and distant metastases, biologic heterogeneity, and the impact of improving systemic therapy. The current data suggest that over the short to intermediate time frame, with increasingly effective systemic therapy, the risk of LR will be less, but the ratio will also be less. Current systemic therapy is most effective in the setting of microscopic residual disease or micrometastases. As systemic therapies are better able to sterilize distant disease, improvements in local-regional control have become more important. As systemic therapy continues to improve such that it can control both distant and local-regional disease, the eventual goal is that local therapy could be completely eliminated; however, that is likely to be sometime into the future. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr MS3-2.
Planned "pay cartel" in southwest England is condemned by BMA and Unison
Authors: J. Wise
Journal: BMJ (2012)

<b>PURPOSE</b> Medicaid programs in all 50 states recently implemented cost-saving strategies, including benefit reductions, cost sharing, and tightened administrative rules. These changes resulted in loss of insurance coverage for thousands of low-income adults nationwide. In this study we assessed the immediate impacts of disrupted and lost Medicaid coverage on adults enrolled in the Oregon Health Plan (OHP) when program changes were implemented. <b>METHODS</b> Data come from baseline survey results of a prospective cohort study designed to assess the impacts of OHP changes on adult beneficiaries. We used bivariate and multivariate analyses to examine the effects of disrupted and lost insurance coverage on unmet health care needs, utilization, and medical debt occurring in the first 10 months after OHP changes were implemented. <b>RESULTS</b> After OHP changes were implemented, 31% of enrolled adults reported losing coverage, and another 15% reported disrupted coverage. Controlling for demographic characteristics, income, and health status, those with disrupted coverage were less likely to have a primary care visit (odds ratio [OR] = .66; <i>P</i> &lt;.05) and more likely to report unmet health care needs (OR = 1.85; <i>P</i> &lt;.01) and medical debt (OR = 1.99; <i>P</i> &lt;.01) when compared with those continuously insured. Those who lost coverage were less likely to have a primary care visit (OR = 0.18; <i>P</i> &lt;.01) and more likely to report unmet health care needs (OR = 5.55; <i>P</i> &lt;.01), unmet medication needs (OR = 2.05; <i>P</i> &lt;01), and medical debt (OR = 3.06; <i>P</i> &lt;.01) than those continuously insured. <b>CONCLUSIONS</b> Medicaid program changes that increase cost sharing and limit enrollment have significant negative impacts on health care access and utilization among Medicaid beneficiaries; these impacts occur rapidly, within the first 10 months after changes.
Abstract 2158: Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in a preclinical model of colorectal cancer.
Authors: Eun-Kee Song, Alicia Purkey, Kevin Quackenbush, Benjamin Cross, Stacey Bagby, John J. Arcaroli, Wells Messersmith
Journal: Cancer Research (2013)

Abstract Background: Dysregulation of c-Src has been shown to modulate many different tumor cell processes. Downstream targets of Src include focal adhesion kinase (FAK), which is important for migration and invasion, and Stat-3, a kinase that enhances survival of cells and angiogenesis. Dysregulation of Src has been shown to be important at various stages of cancer development. Dasatinib is a potent Src/Abl inhibitor and has been shown to have anti-proliferative and anti-invasive activity in many preclinical models. The objective was to determine the anti-proliferative and anti-tumor effects of dasatinib in our preclinical model of colorectal cancer (CRC). Experimental Design: We used colorectal cancer cell lines and patient-derived explants to investigate the efficacy of dasatinib. We treated 45 CRC cell lines with dasatinib for 72 hours and proliferation was assayed by a sulforhodamine B (SRB) assay; an IC50 &amp;lt; 0.1 μM was considered sensitive. We treated 10 patient-derived CRC explants with dasatinib (50 mg/kg/day, administered once-daily) for 28 days to determine in vivo efficacy; a tumor growth inhibition inhibition (TGI) ≥ 50% was considered sensitive. Results: We found that 17 out of 41 CRC cell lines reached an IC50 &amp;lt; 1 uM with dasatinib treatment. The cell lines: HCT116, LS174T, SW1417, WiDR, KM20 and SNU977 all reached an IC50 &amp;lt; 0.08 μM, which is considered to be an achievable dose in the clinic setting. Of 10 CRC explants, grown as xenografts, one showed sensitivity to dasatinib, with a tumor growth inhibiton of 55%. Conclusion: Dasatinib has significant anti-proliferative activity in a subset of CRC cell lines in vitro, but shows moderate efficacy in one out of ten explants treated. We plan on treating an additional 10 CRC explants (20 total) with dasatinib and developing biomarkers of sensitivity or resistance. Citation Format: Eun-Kee Song, Alicia Purkey, Kevin Quackenbush, Benjamin Cross, Stacey Bagby, John J. Arcaroli, Wells Messersmith. Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in a preclinical model of colorectal cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2158. doi:10.1158/1538-7445.AM2013-2158